User Fees, Deadlines and the Review Staff They Fund: How PDUFA Shapes FDA Drug Review

Introduction

Most people in regulatory affairs know PDUFA as the reason an NDA or BLA review has a target date attached to it. Fewer stop to think about what actually produces that date, or where the FDA staff doing the review come from. The Prescription Drug User Fee Act is, at its core, a negotiated funding arrangement: drug companies pay fees when they submit applications, and in exchange FDA commits to specific review timelines and uses a substantial share of that money to hire and retain the reviewers who make those timelines possible. Understanding how that arrangement actually works explains a lot about FDA's review capacity, its hiring cycles, and why submission strategy and user fee planning are rarely separate conversations inside a regulatory affairs department.

How the Fee Structure Actually Works

PDUFA was first enacted in 1992 and has been reauthorized roughly every five years since, each cycle negotiated between FDA and industry before being enacted by Congress alongside the broader user fee legislation that also covers medical devices, generic drugs, and biosimilars. The fees themselves come in a few forms: an application fee paid when a company submits an NDA or BLA requiring clinical data, an annual program fee tied to having prescription drug products on the market, and historically a separate establishment fee for manufacturing facilities, though the exact fee structure has shifted across reauthorization cycles.

These aren't small numbers. Application fees for a single NDA or BLA submission run well into seven figures, which is part of why fee waivers and reductions - available in specific circumstances such as orphan drug designations or for small businesses submitting a first application - matter so much to smaller sponsors. The revenue collected funds a significant share of FDA's human drug review program, supplementing congressional appropriations rather than replacing them; each reauthorization cycle specifies both the fee amounts and the performance commitments FDA takes on in exchange.

What FDA Commits To

In exchange for the fees, FDA negotiates and publishes a detailed set of performance goals, laid out in commitment letters that accompany each reauthorization. These specify target timeframes for completing the first review cycle of a standard or priority application, goals for responding to meeting requests, targets for reviewing certain types of protocol amendments, and increasingly, goals around newer review pathways and communication practices that have been added or refined in more recent cycles. The familiar ten-month standard review and six-month priority review clocks that regulatory affairs professionals plan submissions around trace directly back to these negotiated goals.

FDA's performance against these goals is tracked and reported publicly, and persistent underperformance has real consequences in the next negotiation cycle, since industry representatives sit at the table advocating for goals FDA can actually be held to. This creates an unusual dynamic: the agency being regulated and funded by the fees is also negotiating directly with the companies paying them, with patient advocacy groups and other stakeholders providing input through public meetings that are part of each reauthorization process.

Where the Money Goes: Review Staff

The practical effect most relevant to a regulatory affairs career is what the fee revenue actually funds. A substantial portion goes directly toward hiring, training, and retaining the reviewers, project managers, and supporting scientific staff who conduct drug reviews. FDA's human drug review divisions grew considerably over the PDUFA era precisely because user fee revenue provided a funding stream for review staff that wasn't entirely dependent on the congressional appropriations process, which tends to move slower and less predictably.

This matters for anyone tracking FDA hiring patterns or review capacity. When a reauthorization cycle increases fee revenue or adds new review commitments - such as goals around a new expedited pathway or increased meeting capacity - it typically comes with corresponding FDA hiring targets written into the commitment letter itself. Conversely, periods of reauthorization uncertainty or lapses, which have happened briefly during gaps between authorizations, create real anxiety inside the agency about review capacity and hiring continuity, since user fee revenue can't legally be collected or spent without active authorization in place.

What This Means for Regulatory Affairs Work

For a regulatory affairs professional building a submission strategy, PDUFA goals aren't background information - they directly shape submission timing decisions, meeting request planning, and how a team sets internal deadlines for assembling a complete application. Missing a submission window relative to a PDUFA goal date can mean the difference between a review cycle landing before or after a major agency staffing transition or a backlog created by a surge of other submissions competing for the same review division's time.

The fee negotiation process itself also creates regulatory affairs work that's easy to overlook: companies and industry associations participate in public meetings and comment periods as each reauthorization is negotiated, and larger regulatory affairs and policy teams track these negotiations closely because the resulting commitment letter will shape review timelines and agency expectations for the next five years. Professionals who follow this process closely - not just the headline fee numbers but the specific performance goals and new initiatives in the commitment letter - tend to have a clearer picture of where FDA's review priorities and capacity constraints are actually headed.

Meeting Requests and the Program-Specific Goals

Review timeline goals get most of the attention, but a large portion of each commitment letter is devoted to meeting management goals that shape regulatory affairs work far more often than a single marketing application review does. Type A, B, and C meeting requests - covering everything from a dispute resolution discussion to standard end-of-phase meetings - each carry their own target timeframes for FDA to grant the meeting and respond to briefing materials. For a regulatory affairs team running an active development program, these meeting goals are often the more immediately relevant PDUFA commitment, since a single drug program might involve a dozen or more FDA meetings before a marketing application is ever submitted.

Recent reauthorization cycles have also added or refined goals around specific programs, such as expedited pathways for drugs addressing unmet medical need, and around FDA's communication practices more broadly, including commitments to more frequent informal interactions between review teams and sponsors during development. Tracking exactly what's new in each cycle's commitment letter, not just the headline review clock, is what lets a regulatory affairs team anticipate how FDA's engagement style and capacity will actually function for their specific program.

The Broader User Fee Family

PDUFA doesn't operate in isolation. It's one of several parallel user fee programs covering different product categories: the Generic Drug User Fee Amendments fund generic drug review, the Biosimilar User Fee Act funds biosimilar review, and the Medical Device User Fee Amendments fund device review, each with its own fee structure and negotiated performance goals, generally reauthorized on the same roughly five-year cycle alongside PDUFA. Regulatory professionals working across a mixed portfolio - a company with both branded and biosimilar products, for instance - often need working familiarity with more than one of these programs, since the fee obligations and review goal structures differ meaningfully between them even though the underlying negotiated funding model is similar.

Small Sponsors and Fee Burden

The fee structure affects companies very differently depending on size and pipeline stage. A large pharmaceutical company with dozens of marketed products absorbs application and annual program fees as a predictable, budgeted cost of doing business. A small biotech submitting its first application faces a much heavier relative burden, which is part of why the small business fee waiver exists for qualifying companies submitting their first human drug application - a provision regulatory affairs professionals at emerging companies need to understand and apply for correctly, since missing the qualifying criteria or the application window can mean paying a fee that would otherwise have been waived entirely. Orphan drug designations carry their own fee exemptions as well, reflecting a deliberate policy choice to avoid the fee structure discouraging development for small patient populations where commercial return is inherently limited.

Reauthorization as a Recurring Hiring Signal

Because each reauthorization cycle sets new commitments, the negotiation period itself tends to be a signal worth watching for anyone in regulatory affairs hiring or career planning. New commitments around expedited programs, enhanced communication practices, or capacity for emerging review types typically translate into FDA hiring in the relevant review divisions once the reauthorization is enacted, and sponsors anticipating how those new pathways will work often hire regulatory staff with relevant expertise ahead of the formal rollout. Tracking the public meetings and draft commitment letters that precede each reauthorization isn't just a policy interest; it's a reasonably reliable early indicator of where both agency and industry hiring will concentrate over the following several years.

Conclusion

PDUFA is easy to treat as a fixed backdrop - the ten-month clock everyone plans around - without considering the negotiated funding mechanism that makes the clock meaningful in the first place. For regulatory affairs professionals, understanding how fee revenue connects to FDA's actual review capacity, and how each reauthorization cycle resets both the performance goals and the agency's hiring trajectory, turns PDUFA from background trivia into a genuinely useful piece of context for planning submissions and reading where the field is headed next.